Johnson & Johnson also said during an earnings call Tuesday that it continues to evaluate options for its diabetes care business.
"We're evaluating various options for that business, whether it be a partnership or outright divestiture; whatever is best in terms of giving that business the best position to succeed and obviously, if we were to divest it, getting the right return for our shareholders," said chief financial officer Dominic Caruso on an earnings call Tuesday.
In January, Johnson & Johnson said it was looking at potential strategic options for the diabetes care unit, including LifeScan, Animas and Calibra Medical.
Shares of New Brunswick, N.J.-based Johnson & Johnson, close down about 3.1%, or $3.90 per share, to $121.30 on Tuesday.
Editor's pick: Originally published at 3:36 pm ET.